{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:55:05Z","timestamp":1781754905028,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01724-y","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:54:42Z","timestamp":1779429282000},"page":"3709-3727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Description of the Tranquillo Phase 3 Clinical Trial Designs\/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo"],"prefix":"10.1007","volume":"16","author":[{"given":"Tatjana","family":"Lukic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranab","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Napatalung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Steil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Adiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1724_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236:571\u201392.","journal-title":"Dermatology"},{"key":"1724_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","volume":"35","author":"N Elbuluk","year":"2017","unstructured":"Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017;35:117\u201328.","journal-title":"Dermatol Clin"},{"key":"1724_CR3","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine K, Lim HW, Suzuki T, et al. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1-13.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"1724_CR4","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","volume":"9","author":"J Akl","year":"2024","unstructured":"Akl J, Lee S, Ju HJ, et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health. 2024;9(6):e386\u201396.","journal-title":"Lancet Public Health"},{"key":"1724_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22:757\u201374.","journal-title":"Am J Clin Dermatol"},{"key":"1724_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjd.15199","volume":"177","author":"YC Lai","year":"2017","unstructured":"Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177:708\u201318.","journal-title":"Br J Dermatol"},{"key":"1724_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241445","volume":"15","author":"A Kussainova","year":"2020","unstructured":"Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety: a systematic review and meta-analysis. PLoS ONE. 2020;15:e0241445.","journal-title":"PLoS ONE"},{"key":"1724_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/jdv.14739","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol. 2018;32:1343\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1724_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084409","volume":"25","author":"HL Yamaguchi","year":"2024","unstructured":"Yamaguchi HL, Yamaguchi Y, Peeva E. Pathogenesis of alopecia areata and vitiligo: commonalities and differences. Int J Mol Sci. 2024;25(8):4409.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1724_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/cei\/uxab002","volume":"207","author":"S Faraj","year":"2022","unstructured":"Faraj S, Kemp EH, Gawkrodger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol. 2022;207(1):27\u201343.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"1724_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133772","volume":"5","author":"N Boukhedouni","year":"2020","unstructured":"Boukhedouni N, Martins C, Darrigade AS, et al. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight. 2020;5(11):e133772.","journal-title":"JCI Insight"},{"issue":"4","key":"1724_CR12","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","volume":"142","author":"C Martins","year":"2022","unstructured":"Martins C, Migayron L, Drullion C, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. J Invest Dermatol. 2022;142(4):1194-1205.e7.","journal-title":"J Invest Dermatol"},{"key":"1724_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102842","volume":"24","author":"S Weeks","year":"2021","unstructured":"Weeks S, Harris R, Karimi M. Targeting ITK signaling for T cell-mediated diseases. iScience. 2021;24:102842.","journal-title":"iScience"},{"key":"1724_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14:1235\u201342.","journal-title":"ACS Chem Biol"},{"key":"1724_CR15","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3324\/haematol.2021.280349","volume":"107","author":"A Picod","year":"2022","unstructured":"Picod A, Martino S, Cervera P, et al. Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer\/T-cell lymphoma. Haematologica. 2022;107:2218\u201325.","journal-title":"Haematologica"},{"key":"1724_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","volume":"36","author":"SH Ross","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411\u201333.","journal-title":"Annu Rev Immunol"},{"key":"1724_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613056","volume":"12","author":"K Boniface","year":"2021","unstructured":"Boniface K, Passeron T, Seneschal J, Tulic MK. Targeting innate immunity to combat cutaneous stress: the vitiligo perspective. Front Immunol. 2021;12:613056.","journal-title":"Front Immunol"},{"key":"1724_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaci.2023.09.021","volume":"153","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Del Duca E, Da Rosa JC, et al. Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo. J Allergy Clin Immunol. 2024;153:161-172.e168.","journal-title":"J Allergy Clin Immunol"},{"key":"1724_CR19","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel N, Speeckaert R, Ta\u00efeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37:2173\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1724_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Group VW. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017;77:17\u201329.","journal-title":"J Am Acad Dermatol"},{"key":"1724_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445\u201355.","journal-title":"N Engl J Med"},{"key":"1724_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","volume":"12","author":"F Qi","year":"2021","unstructured":"Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125.","journal-title":"Front Immunol"},{"key":"1724_CR23","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Ta\u00efeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force-Part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37:2185\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1724_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 2023;88:395\u2013403.","journal-title":"J Am Acad Dermatol"},{"key":"1724_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40262-024-01347-6","volume":"63","author":"Y Huh","year":"2024","unstructured":"Huh Y, Wojciechowski J, Purohit VS. Moving beyond boundaries: utilization of longitudinal exposure-response model for bounded outcome score to inform decision making in the accelerated drug development paradigm. Clin Pharmacokinet. 2024;63:381\u201394.","journal-title":"Clin Pharmacokinet"},{"key":"1724_CR26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/art.41316","volume":"72","author":"MF Robinson","year":"2020","unstructured":"Robinson MF, Damjanov N, Stamenkovic B, et al. Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020;72:1621\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"1724_CR27","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","volume":"21","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023;21:2616-2628.e2617.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1724_CR28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/art.43184","volume":"77","author":"SI Danto","year":"2025","unstructured":"Danto SI, Salganik M, Banerjee A, et al. Efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2025;77(10):1337\u201348.","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 1","key":"1724_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0009","volume":"19","author":"S Vermeire","year":"2024","unstructured":"Vermeire S, Allegretti J, Kim H, et al. OP09 oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn\u2019s disease: data from the PIZZICATO umbrella study. J Crohns Colitis. 2024;19(suppl 1):i16.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"1724_CR30","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.291","volume":"7","author":"B King","year":"2023","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib for the treatment of alopecia areata (AA) from the phase 2 and phase 3 ALLEGRO clinical trial program. SKIN J Cutan Med. 2023;7(6):s291. https:\/\/doi.org\/10.25251\/skin.7.supp.291.","journal-title":"SKIN J Cutan Med"},{"key":"1724_CR31","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401:1518\u201329.","journal-title":"Lancet"},{"issue":"6","key":"1724_CR32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/jdv.20526","volume":"39","author":"C Tziotzios","year":"2025","unstructured":"Tziotzios C, Sinclair R, Lesiak A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025;39(6):1152\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1724_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025;192:215\u201327.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01724-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:24:01Z","timestamp":1781753041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01724-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01724-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tatjana Lukic, Pranab Ghosh, Lynne Napatalung, Cunshan Wang, and Samantha K. Kurosky are employees of and hold stock or stock options in Pfizer Inc. Roni Adiri is an employee of and holds stock or stock options in Pfizer Pharmaceutical Israel LTD. Iltefat Hamzavi is a consultant for AbbVie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Merck, Takeda,Teva, Novartis, Jansen, Avita, Galderma, Vimela, and Almirall; an investigator for Pfizer, Incyte, Avita, L'Or\u00e9al\/La Roche-Posay, ITN, and AbbVie; and a board member and past president of the Hidradenitis Suppurativa and Global Vitiligo foundations. Rodney Sinclair has been an investigator for and\/or provided professional services to AbbVie, Aerotek Scientific, Akeso Biopharma, Amgen, Arcutis, Arena Pharmaceuticals, Ascend Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Connect Biopharma, Cutanea, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, MedImmune\/AstraZeneca, Merck Sharp & Dohme, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone Biopharma, Roche, Samson Medical Technologies, Sanofi, Sun Pharma, and UCB Pharma. David Rosmarin has served as a consultant, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, AltruBio, Amgen, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, Viela Bio, and Zura Bio. David Rosmarin is also an Editorial Board member of Dermatology and Therapy. David Rosmarin was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. Leihong Xiang, Kenneth Steil, and Davinder Parsad declare no interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies will be conducted in accordance with the protocol and with the consensus ethical principles derived from international guidelines, including the Helsinki Declaration of 1964 and its later amendments and CIOMS International Ethical Guidelines; applicable International Council for Harmonisation Good Clinical Practice guidelines; and applicable regional laws and regulations, including privacy laws. The protocols, protocol amendments, and other relevant documents are reviewed and approved by the sponsor and submitted by the investigator for review and approval by the institutional review board\/ethics committee before each study can be initiated. All participants or their legally authorized representative must provide written informed consent of their participation in the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}